| |
Atazanavir & Creatinine
|
| |
| |
Download the PDF here
Download the PDF here
In this paper, pdf attached: Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
IN DISCUSSION paper says
In our study, the majority of patients who received ATVor LPV without TDF had stable renal function pre switchand no significant improvement in eGFR post switch,suggesting that these drugs per se have limited nephrotoxicpotential [14]. Several studies have noted an adverse effectof TDFand protease inhibitor coadministration on thekidney: in ACTG 5202, eGFR decline was reported instudy participants who were randomized to ATV withTDF/FTC but not in those who received ATV withabacavir/lamivudine (ABC/3TC) or efavirenz withTDF/FTC or ABC/3TC [26], and in CCTG 578,study participants randomized to receive TDF with a
protease inhibitor (rather than an NNRTI) experiencedgreater eGFR decline [27]. Furthermore, discontinuationof TDF may result in considerable improvement in renalfunction, with eGFR returning to pre-TDF values in approximately three quarters of patients [28]
-----------------------------------
in this study ACTG 5202 ATV+ABC did not cause creatinine decline but ATV+TDF did....
Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1: A Randomized Trial
Original Research |5 April 2011
Eric S. Daar, MD; Camlin Tierney, PhD; Margaret A. Fischl, MD; Paul E. Sax, MD; Katie Mollan, MS; Chakra Budhathoki, PhD; Catherine Godfrey, MD; Nasreen C. Jahed, MPH; Laurie Myers, MS; David Katzenstein, MD; Awny Farajallah, MD; James F. Rooney, MD; Keith A. Pappa, PharmD; William C. Woodward, DO; Kristine Patterson, MD; Hector Bolivar, MD; Constance A. Benson, MD; Ann C. Collier, MD; for the AIDS Clinical Trials Group Study A5202 Team
http://annals.org/aim/article/746912/atazanavir-plus-ritonavir-efavirenz-part-3-drug-regimen-initial-treatment
|
|
| |
| |
|
|
|
